Does Obestatin Level Change in Endometrial Pathologies? A Case-Control Study in A Tertiary Care Hospital

Year 2022, Volume: 4 Issue: 3, 110 - 115, 22.09.2022

Tuba Memur Nagihan Cengaver Canan Tapkan Müjde Can İbanoğlu Burçin Salman Özgü Tayfun Güngör

https://doi.org/10.46969/EZH.1139281

Abstract

Background: The rising incidence of endometrial cancer has been associated with increases in obesity and physical inactivity. We investigated the clinical significance of serum obestatin levels in women with endometrial cancer, endometrial hyperplasia, and age-matched healthy controls.
Material and Methods: The present study was a case-control study conducted at a single center between May 2014 and July 2015. The medical records of 90 patients with a final histopathologic diagnosis after therapeutic curettage for abnormal uterine bleeding were reviewed and categorized by diagnosis. The study population included women with adenocarcinoma of the endometrium (n= 33), hyperplasia of the endometrium (n= 27), and proliferative endometrium (n=30) according to histopathological diagnosis. The women with proliferative endometrium formed the control group.
Results: Endometrial cancer was diagnosed in 33 (36.6%) of the patients who presented to our clinic for abnormal uterine bleeding. In the group with endometrial cancer, the mean age was 55.2 ± 8.6 years. There were no differences in obestatin levels between groups (p > 0.05). In the ROC curve analysis, the area under the curve value was 0.574, and obestatin did not prove to be a significant marker for cancer prediction in the population involved in the study.
Conclusion: This study did not demonstrate a clear association between circulating levels of obestatin and endometrial pathologies.

Keywords

Obestatin, endometrial cancer, endometrial hyperplasia, obesity

Endometrial Patolojilerde Obestatin Düzeyi Değişir Mi? Üçüncü Basamak Hastanede Bir Vaka Kontrol Çalışması

Abstract

Amaç: Artan endometriyal kanser insidansı, obezite ve fiziksel hareketsizlikteki artışlarla ilişkilendirilmiştir. Bu bilgiden yola çıkarak, endometriyal kanserli, endometriyal hiperplazili kadınlarda ve aynı yaştaki sağlıklı kontrollerde serum obestatin düzeylerinin klinik önemini araştırdık.
Gereç ve Yöntem: Bu çalışma Mayıs 2014-Temmuz 2015 tarihleri arasında tek merkezde yürütülen bir vaka-kontrol çalışmasıdır. Anormal uterin kanamaya yönelik terapötik küretaj sonrası kesin histopatolojik tanısı konulan 90 hastanın tıbbi kayıtları incelenmiş ve tanılarına göre kategorize edilmiştir. Çalışma popülasyonu, histopatolojik tanıya göre endometrium adenokarsinomu (n= 33), endometrium hiperplazisi (n=27) ve proliferatif endometrium (n=30) olan kadınları içermiştir. Kontrol grubunu ise proliferatif endometriumlu kadınlar oluşturdu.
Bulgular: Kliniğimize anormal uterin kanama ile başvuran hastaların 33’ünde (%36,6) endometrium kanseri tanısı konuldu. Endometrium kanserli grupta yaş ortalaması 55.2 ± 8.6 yıl idi. Gruplar arasında obestatin seviyelerinde fark yoktu (p > 0.05). ROC eğrisi analizinde, eğrinin altında kalan alan değeri 0,574 idi ve obestatin, çalışmaya dahil edilen popülasyonda kanser tahmini için önemli bir belirteç olduğunu kanıtlamadı.
Sonuç: Bu çalışma, dolaşımdaki obestatin seviyeleri ile endometriyal patolojiler arasında net bir ilişki göstermedi.

Keywords

Obestatin, endometriyal kanser, endometriyal hiperplazi, obezite

References

• World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: AICR; 2007.
• Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet 2016; 387:1094–108.
• Lindemann K, Vatten LJ, Ellstrøm-Engh M, Eskild A. Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study. Br J Cancer 2008; 98:1582–1585.
• Wise MR, Jordan V, Lagas A, et al. Obesity and endometrial hyperplasia and cancer in premenopausal women: a systematic review. Am J Obstet Gynecol 2016; 9378(16): 00225-8.
• Ayhan A, Topfedaisi Ozkan N, Öz M, Kimyon Comert G, Firat Cuylan Z, Çoban G, et L. Impact of lymph node ratio on survival in stage IIIC endometrioid endometrial cancer: a Turkish Gynecologic Oncology Group study. J Gynecol Oncol 2018; 29(4):48.
• Zhang JV, Ren PG, Avsian-Kretchmer O, Luo CW, Rauch R, Klein C, et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin’s effects on food intake. Science 2005;310:996–9.
• Cowan E, Burch KJ, Green BD, Grieve DJ. Obestatin as a key regulator of metabolism and cardiovascular function with emerging therapeutic potential for diabetes. Br J Pharmacol 2016; 173: 2165–2181.
• Anderwald-Stadler M, Krebs M, Promintzer M, Mandl M, Bischof MG, Nowotny P, et al. Plasma obestatin is lower at fasting and not suppressed by insulin in insulin- resistant humans. Am J Physiol Endocrinol Metab 2007;293:1393–8.
• Karamanakos SN, Vagenas K, Kalfarentzos F, Alexandrides TK. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg 2008; 247(3): 401-407.
• Nakahara T, Harada T, Yasuhara D, Shimada N, Amitani, H., Sakoguchi, T.,et al. Plasma obestatin concentrations are negatively correlated with body mass index, insulin resistance index, and plasma leptin concentrations in obesity and anorexia nervosa. Biological Psychiatry 2008; 64(3): 252-255.
• Popelová A, Kákonová A, Hrubá L, Kuneš J, Maletínská L, Železná B. Potential neuroprotective and anti-apoptotic properties of a long-lasting stable analog of ghrelin: an in vitro study using SH-SY5Y cells. Physiol Res 2018; 67(2): 339-346.
• Chopin LK, Seim I, Walpole CM, et al. The ghrelin axis does it have an appetite for cancer progression? Endocr Rev 2012;33: 233–48.
• Tawadros N, Salamonsen LA, Dimitriadis E, et al. Facilitation of decidualization by locally produced ghrelin in the human endometrium. Mol Hum Reprod 2007;13: 483–9.
• Friberg E, Mantzoros C S, Wolk A. Physical activity and risk of endometrial cancer: a population-based prospective cohort study. Cancer epidemiology, biomarkers & prevention 2006; 15(11): 2136-2140.
• Zhang JV, Jahr H, Luo CW, Klein C, Van Kolen K, Ver Donck L, et al. Obestatin induction of early-response gene expression in gastrointestinal and adipose tissues and the mediatory role of G protein-coupled receptor, GPR39. Molecular Endocrinology 2008; 22(6):1464-1475.
• Epelbaum J, Bedjaoui N, Dardennes R, Feng DD, Gardette R, Grouselle D, et al. Role of the ghrelin/obestatin balance in the regulation of neuroendocrine circuits controlling body composition and energy homeostasis. Molecular and Cellular Endocrinology 2010; 314(2): 244-247.
• Zhang JV, Li L, Huang Q, Ren PG. Obestatin receptor in energy homeostasis and obesity pathogenesis. Prog Mol Transl Sci 2013; 114: 89-107.
• Taskin MI, Bulbul E, Adali E, Hismiogulları AA, Inceboz U. Circulating levels of obestatin and copeptin in obese and nonobese women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2015;189: 19-23.
• Noyan V, Bostanci M. Evaluation of effects of diet on serum obestatin levels in over-weight patients with polycystic ovary syndrome. Journal of Obesity and Metabolic Research 2014; 1(4): 230-230.
• Dagli AF, Aydin S, Kocdor H, Gurates B, Sahin İ, Catak Z,et al. Ghrelin expression of endometrium hyperplasia and endometrioid carcinoma. Gynecol Endocrinol 2011;27(3): 199-204.
• Savelli L, Testa AC, Mabrouk M, Zannoni L, Ludovisi M, Seracchioli R, et al. A prospective blinded comparison of the accuracy of transvaginal sonography and frozen section in the assessment of myometrial invasion in endometrial cancer. Gynecologic Oncology 2012;124(3): 549-552.
• Fung JN, Seim I, Wang D, Obermair A, Chopin LK, Chen C. Expression and in vitro functions of the ghrelin axis in endometrial cancer. Horm Cancer 2010;1(5):245-255.
• Cassoni P, Papotti M, Ghè C, Catapano F, Sapino A, Graziani A, et al. Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. The Journal of Clinical Endocrinology & Metabolism 2001;86(4): 1738-1745.
• Gaytan F, Barreiro ML, Chopin LK, Herington AC, Morales C, Pinilla L, et al. Immunolocalization of ghrelin and its functional receptor, the type 1a growth hormone secretagogue receptor, in the cyclic human ovary. J Clin Endocrinol Metab 2003;88:879–887.
• Nurkalem C, Celik H, Dagli F, Gurates B, Kavak B, Dogan Z, Aydin S. Ghrelin and obestatin expression in serous ovarian tumours. Gynecological Endocrinology 2012;28(12): 941-944.
• Soleymani E, Ziari K, Rahmani O, et al. Histopathological findings of endometrial specimens in abnormal uterine bleeding. Arch Gynecol Obstet 2014; 289: 845–849.
• Clarke MA, Long BJ, Sherman ME, et al. Risk assessment of endometrial cancer and endometrial intraepithelial neoplasia in women with abnormal bleeding and implications for clinical management algorithms. Am J Obstet Gynecol 2020; 223(4): 549-551.